5CL-ADB-A

Description

Pharmacokinetics:

5CL-ADB-A, also known as MDMB-4en-PINACA and MDMB-PENINACA, is an indazole-based synthetic cannabinoid in the indazole-3-carboxamide family. Its official scientific nomenclature is methyl (S)-3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (C₂₀H₂₇N₃O₃) [1].

Scientific Studies:

While no official scientific studies have been done on 5CL-ADB-A to date, one 2018 study published in “Forensic Toxicology” compared the potency and mechanisms of several carboxamide-type synthetic cannabinoids. These compounds, like 5CL-ADB-A, have asymmetric carbon, derived from an amide moiety composed of amino acid derivatives. Since they are analogues with similar structures, it’s assumed that these compounds behave in similar ways Indeed, the study found that all such synthetic cannabinoids are agonists that act on both CB1 and CB2 cannabinoid receptors in the body’s endocannabinoid system. This suggests they have a cannabimimetic effect, and can be potentially more potent than cannabis’s psychoactive compound THC, which works by acting on these same cannabinoid receptors. The study looked at AB-FUBINACA, EMB-FUBINACA, 5F-EMB-PINACA, APP-CHMINACA and MDMB-FUBICA, which all have similar structures to 5CL-ADB-A, suggesting this chemical would present similar cannabimimetic effects by acting on CB1 and CB2 receptors [2].

Sources:

1. https://www.caymanchem.com/product/26097/mdmb-4en-pinaca

2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754384/